EMA Refused: Onzeald (etirinotecan pegol) — Nektar Therapeutics UK Limited

View source ↗

Summary

EMA refused approval of Onzeald (etirinotecan pegol) by Nektar Therapeutics UK Limited for breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Onzeald (etirinotecan pegol)

Snippet

Status: Refused. Therapeutic area: Breast Neoplasms. MAH: Nektar Therapeutics UK Limited. Decision date: 08/01/2018